About this Research Topic
Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of molecular biology and the development of targeted drugs, targeted therapy has changed the pattern of lung cancer treatment. In 2004, mutations in the epidermal growth factor receptor (EGFR) were discovered and successfully combined with the development of small molecule tyrosine kinase inhibitors (TKIs), ushering in the era of targeted therapy for non-small cell lung cancer (NSCLC). After nearly 20 years of development, three generations of EGFR-TKIs have been widely used in clinical practice, bringing significant benefits to patients, prolonging survival, and improving quality of life. Molecular targeted therapy has good molecular selectivity, which can efficiently and selectively kill tumor cells, and reduce damage to normal tissues. The adverse reactions of EGFR-TKIs treatment for lung cancer are different from those of traditional treatments such as surgery, radiotherapy, and chemotherapy.
Targeted therapy has completely changed the diagnosis and treatment mode of lung cancer and improved the quality of life of patients. However, targeted therapy will eventually lead to drug resistance and more or less adverse reactions during the treatment process. The efficacy and safety of EGFR-TKIs in the treatment of lung cancer remain of utmost importance. Besides the three generations EGFR-TKIs that have already been clinically applied, we urgently need to develop novel efficient, and low-toxicity EGFR-TKIs. Therefore, we expect to explore the development, application, and side effects of EGFR-TKIs for lung cancer. So as to extend the overall survival and improve the quality of life.
The focus of this Research Topic is to explore the EGFR-TKIs treatment for lung cancer. These may include, but are not limited to:
1. Development of EGFR-TKIs of lung cancer
2. Application of EGFR-TKIs to lung cancer
3. Side effects of EGFR-TKIs of lung cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Targeted therapy has completely changed the diagnosis and treatment mode of lung cancer and improved the quality of life of patients. However, targeted therapy will eventually lead to drug resistance and more or less adverse reactions during the treatment process. The efficacy and safety of EGFR-TKIs in the treatment of lung cancer remain of utmost importance. Besides the three generations EGFR-TKIs that have already been clinically applied, we urgently need to develop novel efficient, and low-toxicity EGFR-TKIs. Therefore, we expect to explore the development, application, and side effects of EGFR-TKIs for lung cancer. So as to extend the overall survival and improve the quality of life.
The focus of this Research Topic is to explore the EGFR-TKIs treatment for lung cancer. These may include, but are not limited to:
1. Development of EGFR-TKIs of lung cancer
2. Application of EGFR-TKIs to lung cancer
3. Side effects of EGFR-TKIs of lung cancer
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: EGFR-TKIs, Lung Cancer, Side Effects, Application
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
